Location: 3716 South Hope Street, suite 313K, Los Angeles, California, United States United States
Founded in: 2014
Stage: Revenue generating
Number of employees: 1-5
Funding history:
- Date: 08/2015, Seed: $97.2 k (post valuation: undisclosed amount).
Short URL:
Followers (28)
Awards and mentions
In the Spring of 2014, Q-Cigarettes took the grand prize of $25,000 at CVS Health at Wake Forest with our novel approach to tobacco dependence.
At Silicon Beach at USC, hosted by the Marshal School of Business, Q-Cigarettes took home 3rd place and $10,000 after being chosen over 70 other companies.


"Quit Together"
Los Angeles, California, United States United States
  • About
  • >
  • Activities
Company description

Our Mission

A tech-startup founded by Public Health professionals helping smokers quit by combining peer support, counseling, and nicotine replacement therapy in a mobile app. 

Our app offers counseling by providing quitters with the tools they need to build a support group, and are a notfication away from receiving words of encouragement from people who care about them. On the medication side, and also through the app, nicotine gum can be purchased to satisy quitters' acute cravings. Quitters can buy their medication themselves, or supporters can buy medication for their quitters.

Independently, Counseling and Nicotine Replacement are both shown to improve a quitters chance of success versus cold-turkey. Our app combines Counseling and Nicotine Replacement in the same place. We call it Combination Therapy, and we know it will give quitters a new, effective option for quitting smoking. 

Our Team

Drew Park, MD/MPH Candidate, Co-Founder

-Drew is an MD/MPH candidate at the Carver College of Medicine at the University of Iowa and the Keck School of Medicine at University of Southern California, respectively. Drew graduated magna cum laude from UCLA and was selected to the Alpha Omega Alpha Honor Medical Society at the Carver College of Medicine. He has also worked under Nobel Prize Laureate, Dr. Ralph Steinman.

William Tsai, MPH, Co-Founder

-Will graduated from Bucknell University with a Bachelor's degree in Chemistry and holds a Master's degree in Public Health from Keck School of Medicine at the University of Southern California. Will has extensive experience in public health education, promotion, and research. 

Owen Parker, MPH, Co-Founder

-Owen received his Master's degree in Public Health from the University of Iowa College of Public Health, where he focused on social and behavioral health, pathology and toxicology. He has also done research with infectious disease and public health policy.

Our Advisors

Raymond Hohl MD, PhD

-Dr. Hohl is the Director of the Penn State Hershey Cancer Institute, Emeritus Professor of Internal Medicine at the University of Iowa Carver College of Medicine, and founder of Terpenoid Therapeutics.

Andrew Gray, PhD, CEO Vali Nanomedical

-Dr. Gray is the Co-Founder and CEO of Vali Nanomedical Corporation specialized in nanotechnology for medical purposes. He received his PhD at the University of Southern California in 2011.

Edythe London, PhD

-Dr. London is the Thomas and Katherine Pike Professor of Addiction Studies and Director of the UCLA Laboratory of Molecular Pharmacology at the David Geffen School of Medicine at UCLA.

Frank Mastronuzzi MBA

-Frank Mastronuzzi is the CFO of Curbstand, Inc. He is also the Co-Founder and Chief Love Officer of OneGoodCrush, a dating app for LGBTQ singles.







Business model

In the first tier of access, the general population can download the Q-Cigarettes App for free. Users enjoy all of its benefits including Quitters and Supporters both being able to escalate care by purchasing nicotine replacement therapy.
In the second tier, patients within partnered healthcare networks download the app for free. The company gains referrals. The users gain a novel healthcare provider-initiated intervention. And the healthcare network gains an IT servicer who will satisfy HEDIS and quality measurement reporting for them – a process currently in the earliest stages of development and one that has the potential to increase healthcare provider reimbursement.In advance of our hard launch in January 2016, we have secured referral commitments from over fifteen healthcare providers and practices.


Competitive advantage

Initially, we plan to sell Q-Cigarettes as a consumer product to speed our launch and avoid FDA oversight. Future iterations of Q-Cigarettes including those described in our pending patent application have been pre-classified as Class I drug-device combos.

We have already secured a number of agreements by healthcare providers in Iowa and Southern California to make referrals to the Q-Cigarettes Program at launch. We are aggressively making more contacts and anticipate continued success. To facilitate adoption by late adopters, we are writing the first of a series of clinical study protocols for the Program.

We have or will place intellectual property, FDA regulatory, scientific and first-to-market barriers to sustain a competitive advantage.



Investor Deafult Image
Eric Kuo - Unconfirmed
Investor Deafult Image
Jimmy Hsu - Unconfirmed
Investor Deafult Image
Brian Wada - Unconfirmed